Plasma and Intracellular Concentrations of Raltegravir and Etravirine Administered Once Daily (800 mg and 400 mg, Respectively) Compared With Standard Dosing (400 mg and 200 mg/12 h) in Patients With HIV Infection.

Trial Profile

Plasma and Intracellular Concentrations of Raltegravir and Etravirine Administered Once Daily (800 mg and 400 mg, Respectively) Compared With Standard Dosing (400 mg and 200 mg/12 h) in Patients With HIV Infection.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jun 2011

At a glance

  • Drugs Etravirine (Primary) ; Raltegravir (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacokinetics
  • Acronyms RAET
  • Most Recent Events

    • 07 Feb 2011 Actual end date (Jan 2001) added as reported by ClinicalTrials.gov.
    • 07 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 14 May 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top